TrialJCI insight2019

Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.

Shaundra Eichstadt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.